ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 21 Issue : 3
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function [Anatol J Cardiol]
Anatol J Cardiol. 2016; 16(5): 344-348 | DOI: 10.5152/AnatolJCardiol.2015.6191  

Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function

Selcen Yakar Tülüce1, Kamil Tülüce2, Zafer Çil3, Sadık Volkan Emren1, Zehra İlke Akyıldız1, Oktay Ergene4
1Department Of Cardiology, İzmir Katip Çelebi University Atatürk Training And Research Hospital; İzmir- Turkey
2Clinics Of Cardiology, Karşıyaka State Hospital; İzmir- Turkey
3Medical Biochemistry, Karşıyaka State Hospital; İzmir- Turkey
4Department Of Cardiology, Faculty Of Medicine, Dokuz Eylül University; İzmir- Turkey

Objective: Cardiac fibrosis is an important contributor to adverse left ventricular (LV) remodeling and arrhythmias in patients with hypertrophic cardiomyopathy (HCM). Galectin-3 (Gal-3) is a novel marker of cardiac fibrosis and inflammation. In this study, we investigated Gal-3 levels in patients with HCM and controls and assessed the relationship between Gal-3 level and echocardiographic indices using strain echocardiography in patients with HCM.
Methods: Forty patients with HCM in sinus rhythm and 35 healthy controls were prospectively enrolled in this case-control study. The HCM diagnosis was based on two-dimensional echocardiographic demonstration of a hypertrophied and non-dilated left ventricle (LV) with a wall thickness ≥15 mm in one or more LV myocardial segments in the absence of any cardiac or systemic disease capable of inducing LV hypertrophy. Patients with one of the followings were excluded: coronary artery disease, atrial fibrillation episodes on 24-h Holter electrocardiogram (ECG) monitoring, history of an invasive intervention to alleviate an LV outflow (LVOT) obstruction, inadequate image quality, renal disease, diabetes mellitus, hyperlipidemia, liver cirrhosis, and pulmonary fibrosis. Global LV longitudinal, circumferential strain and strain rates, peak torsion, and LV mass index (LVMI) of all subjects were assessed by echocardiography. Gal-3 levels were measured in all subjects.
Results: Left ventricular global longitudinal strain (-13.37±4.6% vs. -18.93±2.5%, p<0.001) and strain rate (0.66±0.22 s-1 vs. 1.08±0.14 s-1, respectively; p<0.001) values were lower in patients with HCM than in controls. Gal-3 levels were significantly higher in patients with HCM than in controls (16.9±6.64 ng/mL vs. 13.21±3.42 ng/mL, p=0.005). Gal-3 levels were associated with the thickness of the interventricular septum (r=0.444, p=0.004) and LVMI (r=0.365, p=0.021); however, they were not associated with LV global longitudinal strain (p=0.42) or strain rate (p=0.28).
Conclusion: Gal-3 levels increased and were correlated with the degree of LV hypertrophy in patients with HCM. Gal-3 is not a good marker of decreased myocardial LV diastolic and systolic functions in these patients. (Anatol J Cardiol 2016; 16: 344-8)

Keywords: Galectin-3, hypertrophic cardiomyopathy, left ventricular mass index, strain imaging


Selcen Yakar Tülüce, Kamil Tülüce, Zafer Çil, Sadık Volkan Emren, Zehra İlke Akyıldız, Oktay Ergene. Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function. Anatol J Cardiol. 2016; 16(5): 344-348

Corresponding Author: Selcen Yakar Tülüce, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2018 Turkish Society of Cardiology